Viking Therapeutics

VKTX

Market cap $3.83B

Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Viking Therapeutics could enter the weight loss market by 2029. The company's leading candidate looks very promising.

SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Piper Sandler 37th Annual Healthcare Conference. The conference will take place December 2-4, 2025, in New York, New York.

If you want to invest in top healthcare stocks, both of these are worth consideration. Pfizer is moving past the pandemic era, and tremendous growth could be ahead.

The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it's set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanley.

Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?

Mid-cap stocks can come with risks, but also a ton of upside in the long run. The stocks listed here offer exciting growth opportunities across multiple industries.

Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.

Viking Therapeutics stock yo-yoed Wednesday after the company said it overenrolled one of its final-phase studies for its weight-loss shot.